Guangzhou Kingmed Diagnostics Group Co., Ltd. (603882.SS)
CNY 31.24
(-1.26%)
CNY 31.24
(-1.26%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 3.11 Billion CNY | -56.19% |
| 2022 | 6.67 Billion CNY | 18.17% |
| 2021 | 5.64 Billion CNY | 46.76% |
| 2020 | 3.84 Billion CNY | 85.02% |
| 2019 | 2.08 Billion CNY | 18.37% |
| 2018 | 1.75 Billion CNY | 13.16% |
| 2017 | 1.55 Billion CNY | 13.83% |
| 2016 | 1.36 Billion CNY | 24.33% |
| 2015 | 1.09 Billion CNY | 31.43% |
| 2014 | 834.94 Million CNY | 39.78% |
| 2013 | 597.32 Million CNY | 55.01% |
| 2012 | 385.34 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 713.68 Million CNY | 21.64% |
| 2024 Q1 | 586.72 Million CNY | -16.5% |
| 2024 Q3 | 622.59 Million CNY | -12.76% |
| 2023 Q3 | 691.77 Million CNY | -20.27% |
| 2023 Q4 | 702.64 Million CNY | 1.57% |
| 2023 FY | 2.92 Billion CNY | -56.19% |
| 2023 Q1 | 802.91 Million CNY | -33.25% |
| 2023 Q2 | 867.68 Million CNY | 8.07% |
| 2022 Q3 | 1.75 Billion CNY | 0.73% |
| 2022 Q2 | 1.74 Billion CNY | -11.35% |
| 2022 Q1 | 1.96 Billion CNY | 20.74% |
| 2022 FY | 6.67 Billion CNY | 18.17% |
| 2022 Q4 | 1.2 Billion CNY | -31.57% |
| 2021 Q2 | 1.26 Billion CNY | 0.47% |
| 2021 FY | 5.64 Billion CNY | 46.76% |
| 2021 Q4 | 1.63 Billion CNY | 9.52% |
| 2021 Q1 | 1.26 Billion CNY | 6.64% |
| 2021 Q3 | 1.48 Billion CNY | 17.44% |
| 2020 Q1 | 436.02 Million CNY | -15.74% |
| 2020 Q2 | 1.11 Billion CNY | 156.81% |
| 2020 FY | 3.84 Billion CNY | 85.02% |
| 2020 Q4 | 1.18 Billion CNY | 6.6% |
| 2020 Q3 | 1.1 Billion CNY | -0.89% |
| 2019 Q1 | 440.21 Million CNY | -4.77% |
| 2019 FY | 2.08 Billion CNY | 18.37% |
| 2019 Q4 | 517.44 Million CNY | -6.06% |
| 2019 Q3 | 550.81 Million CNY | -3.65% |
| 2019 Q2 | 571.64 Million CNY | 29.86% |
| 2018 Q4 | 462.26 Million CNY | -1.6% |
| 2018 FY | 1.75 Billion CNY | 13.16% |
| 2018 Q3 | 469.79 Million CNY | -2.16% |
| 2018 Q2 | 480.15 Million CNY | 39.15% |
| 2018 Q1 | 345.05 Million CNY | -11.38% |
| 2017 Q1 | 319.09 Million CNY | -14.01% |
| 2017 Q3 | 413.29 Million CNY | -4.14% |
| 2017 Q4 | 389.37 Million CNY | -5.79% |
| 2017 Q2 | 431.16 Million CNY | 35.12% |
| 2017 FY | 1.55 Billion CNY | 13.83% |
| 2016 Q4 | 371.07 Million CNY | 2.3% |
| 2016 Q3 | 362.72 Million CNY | 0.0% |
| 2016 FY | 1.36 Billion CNY | 24.33% |
| 2015 Q4 | 305.92 Million CNY | 0.0% |
| 2015 FY | 1.09 Billion CNY | 31.43% |
| 2014 FY | 834.94 Million CNY | 39.78% |
| 2013 FY | 597.32 Million CNY | 55.01% |
| 2012 FY | 385.34 Million CNY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 2.41 Billion CNY | -28.797% |
| Joinn Laboratories(China)Co.,Ltd. | 1.01 Billion CNY | -207.577% |
| WuXi AppTec Co., Ltd. | 16.27 Billion CNY | 80.863% |
| Autobio Diagnostics Co., Ltd. | 2.83 Billion CNY | -10.002% |
| Thalys Medical Technology Group Inc. | 389.73 Million CNY | -699.283% |
| Chemclin Diagnostics Co., Ltd. | 335.61 Million CNY | -828.168% |